Who are DPK-060's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Induction- PF-06480605 450 mg SC Q4W, Ixazomib plus low-dose lenalidomide, Korean Red Ginseng (KRG), Chloroquine prophylaxis, Glatiramer acetate (Copaxone), PF-06863135 + lenalidomide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dpk-060.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

DPK-060 — Competitive Intelligence Brief

DPK-060 (DPK-060) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator. Area: Dermatology.

phase 2 Immunomodulator IL-17 receptor Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

DPK-060 (DPK-060) — DermaGen AB. DPK-060 is a topical treatment that modulates the immune response to reduce inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DPK-060 TARGET	DPK-060	DermaGen AB	phase 2	Immunomodulator	IL-17 receptor
Induction- PF-06480605 450 mg SC Q4W	induction-pf-06480605-450-mg-sc-q4w	Pfizer	marketed	small molecule	IL-17 receptor
Ixazomib plus low-dose lenalidomide	Ixazomib plus low-dose lenalidomide	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	Proteasome inhibitor and immunomodulatory agent	Proteasome and cereblon
Korean Red Ginseng (KRG)	Korean Red Ginseng (KRG)	Pusan National University Hospital	marketed	Herbal adaptogen / immunomodulator
Chloroquine prophylaxis	Chloroquine prophylaxis	Radboud University Medical Center	marketed	Antimalarial; immunomodulator	Plasmodium falciparum heme detoxification pathway; toll-like receptors
Glatiramer acetate (Copaxone)	Glatiramer acetate (Copaxone)	Federal University of São Paulo	marketed	Immunomodulator; disease-modifying therapy (DMT)	T cell receptor (indirect); myelin basic protein mimic
PF-06863135 + lenalidomide	pf-06863135-lenalidomide	Pfizer	marketed	small molecule + immunomodulatory drug	unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator class)

Actavis Mid-Atlantic LLC · 1 drug in this class
Active Biotech AB · 1 drug in this class
Air Force Military Medical University, China · 1 drug in this class
Astellas Pharma Inc · 1 drug in this class
Bayer · 1 drug in this class
Beijing Children's Hospital · 1 drug in this class
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 drug in this class
Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri · 1 drug in this class
Chang Gung Memorial Hospital · 1 drug in this class
ALK-Abelló A/S · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DPK-060 — Competitive Intelligence Brief. https://druglandscape.com/ci/dpk-060. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab